Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema (right eye)
ICD-10 E09.3491 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema (right eye).
E09.3491 refers to diabetes mellitus that has been induced by drugs or chemicals, characterized by severe nonproliferative diabetic retinopathy affecting the right eye without the presence of macular edema. This condition arises when certain medications or toxic substances lead to insulin resistance or impaired insulin secretion, resulting in elevated blood glucose levels. The severe nonproliferative diabetic retinopathy indicates significant retinal damage, which can lead to vision impairment if not managed appropriately. The absence of macular edema suggests that while there is retinal damage, the central vision area remains unaffected. Management of this condition typically involves controlling blood glucose levels through insulin therapy or oral hypoglycemics, regular monitoring of HbA1c levels, and ophthalmologic evaluations to assess the progression of retinopathy. The interplay between diabetes management and the effects of the inducing agent is crucial for patient care.
Detailed history of diabetes onset, medication history, and HbA1c levels.
Patients presenting with new-onset diabetes due to medication, requiring insulin management.
Close monitoring of blood glucose levels and potential adjustments in therapy based on the inducing agent.
Comprehensive eye examination reports, including retinal imaging and assessment of retinopathy severity.
Patients with diabetes presenting for routine eye exams or with vision changes.
Documentation must clearly state the absence of macular edema and the specific eye affected.
Used for follow-up visits for diabetes management.
Document patient's diabetes management plan, including medications and HbA1c levels.
Endocrinologists should ensure comprehensive documentation of diabetes control.
Specifying the eye affected is crucial for treatment planning and monitoring of diabetic retinopathy, as it can influence management strategies and patient outcomes.
